

University of Colorado Therapeutics in Clinical Trials

Drug	Market	Licensee	IND	Phase I	Phase II	Phase III	Approved
Kineret®	Rheumatoid arthritis	Biovitrum					
Macugen®	Wet age-related macular degeneration	OSI					
Zostavax®	Post-herpetic neuralgia	Merck					
Botulinum A toxin use	Neurogenic overactive bladder	Allergan					
Botulinum A toxin use	Overactive bladder r/t spinal cord injury or MS	Allergan					
Macugen®	Diabetic macular edema	OSI/Pfizer					
VZV vaccine	Herpes Zoster prevention	GSK					
GI-5005	Chronic hepatitis (HCV) viral infection	Globelmmune					
ASI411	Renal cancer	Archemix/Antisoma					
Botulinum A toxin use	Benign prostatic hyperplasia (BPH)	Allergan					
ASI411	Acute myeloid leukemia	Archemix/Antisoma					
Macugen®	Macular edema/central retinal vein occlusion	OSI/Pfizer					
GRNVAC1	Acute myelogenous leukemia	Geron					
GI-4000	Pancreatic cancer	Globelmmune					
ARC1779	Thrombotic thrombocytopenic purpura (TTP)	Archemix					
REG1	Anti-coagulation/CABG	Archemix/Regado					
REG1	Anti-coagulation/PCI	Archemix/Regado					
AV411 (Ibutilast®) use	Opioid withdrawal	Avigen (NIDA study)					
ARC1779	Carotid endarterectomy (CEA)	Archemix					
ARC1779	Thrombotic microangiopathies (TMA)	Archemix					
NU172	Anti-coagulation/CABG	Archemix/ARCA biopharma					
GI-4000	Non-small cell lung cancer (NSCLC)	Globelmmune					
Macugen®	Diabetic iris neovascularization	OSI/Pfizer					
E-10030	Age-related macular degeneration	Archemix/Ophthotech					
V934/V935	Solid tumors	Geron/Merck					
GI-6207	Metastatic cancers	Globelmmune					
ARC1905	Age-related macular degeneration	Archemix/Ophthotech					
GI-8000	Avian/seasonal flu	Globelmmune					

IN PROGRESS

COMPLETED

University of Colorado Technology Transfer Office

www.cu.edu/techtransfer

To learn more about the technologies listed here, contact:

Rick Silva
303.724.0222, rick.silva@cu.edu